Mary V Relling

Author PubWeight™ 249.04‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007 17.68
2 Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002 11.83
3 Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009 10.54
4 BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 2008 10.12
5 Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 2009 7.95
6 Acute lymphoblastic leukemia. N Engl J Med 2004 7.83
7 Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med 2014 5.37
8 Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat Genet 2011 4.93
9 Implementing genomic medicine in the clinic: the future is here. Genet Med 2013 4.89
10 Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood 2004 4.21
11 Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med 2004 4.16
12 Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nat Genet 2009 3.71
13 Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N Engl J Med 2003 3.57
14 Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 2011 3.40
15 Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group. J Clin Oncol 2011 3.05
16 Moving towards individualized medicine with pharmacogenomics. Nature 2004 2.99
17 Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood 2012 2.82
18 Results of therapy for acute lymphoblastic leukemia in black and white children. JAMA 2003 2.77
19 Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA 2009 2.72
20 Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism. Lancet Oncol 2010 2.52
21 Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Res 2011 2.52
22 Gene expression signatures predictive of early response and outcome in high-risk childhood acute lymphoblastic leukemia: A Children's Oncology Group Study [corrected]. J Clin Oncol 2008 2.51
23 The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin Pharmacol Ther 2013 2.39
24 Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. JAMA 2007 2.38
25 Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood 2010 2.37
26 Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia. J Clin Oncol 2008 2.29
27 Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol 2009 2.20
28 Pharmacogenomics: challenges and opportunities. Ann Intern Med 2006 1.96
29 Karyotypic abnormalities create discordance of germline genotype and cancer cell phenotypes. Nat Genet 2005 1.94
30 Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. Blood 2012 1.90
31 Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemia. Blood 2008 1.89
32 Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia. Blood 2011 1.88
33 Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr Drug Metab 2014 1.88
34 Development and implementation of a pharmacist-managed clinical pharmacogenetics service. Am J Health Syst Pharm 2011 1.85
35 Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations. J Natl Cancer Inst 2013 1.81
36 Development and use of active clinical decision support for preemptive pharmacogenomics. J Am Med Inform Assoc 2013 1.80
37 A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia. Blood 2014 1.80
38 Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells. Nat Genet 2003 1.79
39 Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. Blood 2008 1.79
40 Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J Clin Oncol 2003 1.75
41 Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. J Clin Oncol 2013 1.75
42 Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies. Blood 2011 1.67
43 PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity. Hum Mol Genet 2012 1.66
44 Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial. J Clin Oncol 2011 1.60
45 Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia. Cancer Cell 2005 1.58
46 Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. Annu Rev Pharmacol Toxicol 2014 1.58
47 Pharmacokinetics of daunorubicin and daunorubicinol in infants with leukemia treated in the interfant 99 protocol. Pediatr Blood Cancer 2010 1.54
48 Risk of adverse events after completion of therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 2005 1.53
49 Thiopurine methyltransferase in acute lymphoblastic leukemia. Blood 2006 1.52
50 Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood 2007 1.52
51 Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a report from the children's oncology group. J Clin Oncol 2012 1.52
52 PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics. Am J Med Genet C Semin Med Genet 2014 1.49
53 Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2011 1.46
54 Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. J Clin Invest 2005 1.46
55 Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. Nat Genet 2013 1.45
56 Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood 2005 1.42
57 Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. Cancer 2008 1.42
58 ARID5B genetic polymorphisms contribute to racial disparities in the incidence and treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol 2012 1.39
59 In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile. PLoS Med 2008 1.37
60 Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cells. Nat Med 2011 1.34
61 Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease. J Clin Oncol 2014 1.31
62 Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J Natl Cancer Inst 2010 1.30
63 Genome-wide association studies in pharmacogenomics: successes and lessons. Pharmacogenet Genomics 2013 1.30
64 PharmGKB summary: methotrexate pathway. Pharmacogenet Genomics 2011 1.27
65 A mouse model for glucocorticoid-induced osteonecrosis: effect of a steroid holiday. J Orthop Res 2009 1.25
66 A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 2008 1.18
67 Genome-wide study of methotrexate clearance replicates SLCO1B1. Blood 2012 1.17
68 Improved prognosis for older adolescents with acute lymphoblastic leukemia. J Clin Oncol 2010 1.16
69 Proximal tubular secretion of creatinine by organic cation transporter OCT2 in cancer patients. Clin Cancer Res 2012 1.15
70 Pharmacogenetics of human carbonyl reductase 1 (CBR1) in livers from black and white donors. Drug Metab Dispos 2008 1.12
71 Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. Blood 2003 1.10
72 Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. J Clin Oncol 2014 1.10
73 Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia. Blood 2006 1.10
74 De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo. Blood 2002 1.08
75 Modeling mechanisms of in vivo variability in methotrexate accumulation and folate pathway inhibition in acute lymphoblastic leukemia cells. PLoS Comput Biol 2010 1.07
76 Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 2008 1.05
77 The SWI/SNF chromatin-remodeling complex and glucocorticoid resistance in acute lymphoblastic leukemia. J Natl Cancer Inst 2008 1.04
78 Nomenclature for alleles of the thiopurine methyltransferase gene. Pharmacogenet Genomics 2013 1.03
79 Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies. Pharmacogenetics 2002 1.03
80 A mathematical model of in vivo methotrexate accumulation in acute lymphoblastic leukemia. Cancer Chemother Pharmacol 2002 1.02
81 Expression of SMARCB1 modulates steroid sensitivity in human lymphoblastoid cells: identification of a promoter SNP that alters PARP1 binding and SMARCB1 expression. Hum Mol Genet 2007 1.01
82 HPLC determination of thiopurine nucleosides and nucleotides in vivo in lymphoblasts following mercaptopurine therapy. Clin Chem 2002 1.01
83 Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients. Cancer 2012 0.99
84 Acute lymphoblastic leukemia with TEL-AML1 fusion has lower expression of genes involved in purine metabolism and lower de novo purine synthesis. Blood 2004 0.98
85 A substrate specific functional polymorphism of human gamma-glutamyl hydrolase alters catalytic activity and methotrexate polyglutamate accumulation in acute lymphoblastic leukaemia cells. Pharmacogenetics 2004 0.96
86 A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871. Clin Cancer Res 2007 0.96
87 Hyaluronan synthase 3 variant and anthracycline-related cardiomyopathy: a report from the children's oncology group. J Clin Oncol 2014 0.96
88 CRHR1 polymorphisms predict bone density in survivors of acute lymphoblastic leukemia. J Clin Oncol 2008 0.96
89 Differential effects of targeted disruption of thiopurine methyltransferase on mercaptopurine and thioguanine pharmacodynamics. Cancer Res 2007 0.95
90 Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse. Cancer 2008 0.95
91 Genetic studies of a cluster of acute lymphoblastic leukemia cases in Churchill County, Nevada. Environ Health Perspect 2007 0.94
92 Lymphoid gene expression as a predictor of risk of secondary brain tumors. Genes Chromosomes Cancer 2005 0.94
93 Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment. Blood 2005 0.93
94 Evidence for age as a modifier of genetic associations for lipid levels. Ann Hum Genet 2011 0.92
95 Acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2002 0.91
96 Integrated analysis of pharmacologic, clinical and SNP microarray data using Projection Onto the Most Interesting Statistical Evidence with Adaptive Permutation Testing. Int J Data Min Bioinform 2011 0.91
97 Thiopurine pathway. Pharmacogenet Genomics 2010 0.90
98 High-throughput asparaginase activity assay in serum of children with leukemia. Int J Clin Exp Med 2013 0.90
99 Primary epiphyseal arteriopathy in a mouse model of steroid-induced osteonecrosis. Am J Pathol 2013 0.89
100 Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes. Pharmacogenomics 2014 0.89
101 Higher activity of polymorphic NAD(P)H:quinone oxidoreductase in liver cytosols from blacks compared to whites. Toxicol Lett 2006 0.89
102 A new system identification approach to identify genetic variants in sequencing studies for a binary phenotype. Hum Hered 2014 0.87
103 Limited and optimal sampling strategies for etoposide and etoposide catechol in children with leukemia. J Pharmacokinet Pharmacodyn 2002 0.87
104 Childhood acute lymphoblastic leukemia. Rev Clin Exp Hematol 2002 0.86
105 Late-onset delayed excretion of methotrexate. Cancer Chemother Pharmacol 2004 0.86
106 Methotrexate intracellular disposition in acute lymphoblastic leukemia: a mathematical model of gamma-glutamyl hydrolase activity. Clin Cancer Res 2002 0.86
107 CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes. Drug Metab Dispos 2004 0.86
108 Substrain-specific differences in survival and osteonecrosis incidence in a mouse model. Comp Med 2012 0.85
109 Epigenetic regulation of human gamma-glutamyl hydrolase activity in acute lymphoblastic leukemia cells. Am J Hum Genet 2006 0.85
110 Role of pharmacogenomics and pharmacodynamics in the treatment of acute lymphoblastic leukaemia. Best Pract Res Clin Haematol 2002 0.84
111 Population PK/PD model of homocysteine concentrations after high-dose methotrexate treatment in patients with acute lymphoblastic leukemia. PLoS One 2012 0.84
112 Global gene expression as a function of germline genetic variation. Hum Mol Genet 2005 0.83
113 Etoposide induces chimeric Mll gene fusions. FASEB J 2003 0.82
114 Pharmacokinetics and pharmacodynamics of oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia. J Clin Oncol 2003 0.82
115 Etoposide pathway. Pharmacogenet Genomics 2009 0.82
116 Prognostic impact of absolute lymphocyte counts at the end of remission induction in childhood acute lymphoblastic leukemia. Cancer 2013 0.82
117 Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments. Cancer Chemother Pharmacol 2013 0.82
118 Neuropathic pain during treatment for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2011 0.81
119 Genetic predictors of glucocorticoid-induced hypertension in children with acute lymphoblastic leukemia. Pharmacogenet Genomics 2008 0.81
120 Concordant gene expression in leukemia cells and normal leukocytes is associated with germline cis-SNPs. PLoS One 2008 0.80
121 Polymorphisms in the MLL breakpoint cluster region (BCR). Hum Genet 2003 0.80
122 The thirteenth international childhood acute lymphoblastic leukemia workshop report: La Jolla, CA, USA, December 7-9, 2011. Pediatr Blood Cancer 2012 0.79
123 Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia. Clin Pharmacol Ther 2003 0.79
124 Are children with lesser-risk B-lineage acute lymphoblastic leukemia curable with antimetabolite therapy? Nat Clin Pract Oncol 2008 0.78
125 Increased CYP3A4 copy number in TONG/HCC cells but not in DNA from other humans. Pharmacogenet Genomics 2006 0.77
126 Merging Electronic Health Record Data and Genomics for Cardiovascular Research: A Science Advisory From the American Heart Association. Circ Cardiovasc Genet 2016 0.77
127 Prophylactic Trimethoprim-Sulfamethoxazole Does Not Affect Pharmacokinetics or Pharmacodynamics of Methotrexate. J Pediatr Hematol Oncol 2016 0.76
128 Is mega dose of methotrexate beneficial to patients with acute lymphoblastic leukemia? Leuk Lymphoma 2006 0.76
129 Can the genotoxicity of chemotherapy be predicted? Lancet 2004 0.76
130 Host thiopurine methyltransferase status affects mercaptopurine antileukemic effectiveness in a murine model. Pharmacogenet Genomics 2014 0.76
131 Continue to study childhood ALL. Blood 2008 0.75
132 Effect of allopurinol versus urate oxidase on methotrexate pharmacokinetics in children with newly diagnosed acute lymphoblastic leukemia. Cancer 2010 0.75
133 A Semiparametric Bayesian Model for Repeatedly Repeated Binary Outcomes. J R Stat Soc Ser C Appl Stat 2008 0.75
134 Genetics of pleiotropic effects of dexamethasone. Pharmacogenet Genomics 2017 0.75